Biotech niche Small biotech company focused on using Dictyostelid amoebae as biocontrol agents for agriculture, medicine, and industry. Potential sales opening with specialized biocontrol distributors and research institutions seeking novel antimicrobial solutions.

Antimicrobial scope Technology targets antibiotic resistant and common pathogens, including MRSA and Pseudomonas, and disrupts biofilms. Opportunity to engage hospital networks, medical device sterilization providers, and wound care product manufacturers seeking enhanced disinfection and infection control.

Regulatory & funding Recent Series A funding indicates investor confidence and growing validation. Leverage interest to pitch grant-ready collaborations, pilot programs, or co-development with larger biotech, agri-tech, or healthcare players pursuing innovative antimicrobial strategies.

Operational scale Current team is lean (2-10 employees) with a tech stack aligned to cloud and web capabilities. Sales strategy could emphasize external partnerships, contract research, and licensing deals rather than in-house manufacturing scalability.

Market expansion Potential applications across agriculture, healthcare, and food processing create cross-vertical selling angles. Target large agri-producers, medical device sterilizers, hospital systems, and food industry processors seeking biofilm control and contamination prevention.